417 related articles for article (PubMed ID: 32799550)
21. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.
Cervello M; McCubrey JA; Cusimano A; Lampiasi N; Azzolina A; Montalto G
Oncotarget; 2012 Mar; 3(3):236-60. PubMed ID: 22470194
[TBL] [Abstract][Full Text] [Related]
22. [Clinical advances in targeted therapy and immunotherapy for hepatocellular carcinoma].
Zhang DZ; Niu JQ
Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):834-837. PubMed ID: 31941237
[TBL] [Abstract][Full Text] [Related]
23. Novel molecular therapies in hepatocellular carcinoma.
Faivre S; Bouattour M; Raymond E
Liver Int; 2011 Jan; 31 Suppl 1():151-60. PubMed ID: 21205154
[TBL] [Abstract][Full Text] [Related]
24. Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future.
Stotz M; Gerger A; Haybaeck J; Kiesslich T; Bullock MD; Pichler M
Anticancer Res; 2015 Nov; 35(11):5737-44. PubMed ID: 26503994
[TBL] [Abstract][Full Text] [Related]
25. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.
Chan LL; Chan SL
Expert Opin Emerg Drugs; 2021 Mar; 26(1):39-52. PubMed ID: 33724135
[TBL] [Abstract][Full Text] [Related]
26. Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check.
Lee A; Lee FC
Front Med; 2020 Jun; 14(3):273-283. PubMed ID: 31863306
[TBL] [Abstract][Full Text] [Related]
27. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
Carloni R; Rizzo A; Ricci AD; Frega G; Federico AD; Palloni A; Marco MD; Gadaleta-Caldarola G; Brandi G
Future Oncol; 2022 Mar; 18(8):1023-1034. PubMed ID: 35109664
[TBL] [Abstract][Full Text] [Related]
28. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond.
Kudo M
World J Gastroenterol; 2019 Feb; 25(7):789-807. PubMed ID: 30809080
[TBL] [Abstract][Full Text] [Related]
29. Future treatment option for hepatocellular carcinoma: a focus on brivanib.
Kudo M
Dig Dis; 2011; 29(3):316-20. PubMed ID: 21829023
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data.
Harkus U; Wankell M; Palamuthusingam P; McFarlane C; Hebbard L
Semin Cancer Biol; 2022 Nov; 86(Pt 3):799-815. PubMed ID: 35065242
[TBL] [Abstract][Full Text] [Related]
31. [Status Quo and Development of Immunotherapy for Hepatocellular Carcinoma].
Wang T; Wang WT
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 May; 54(3):692-698. PubMed ID: 37248607
[TBL] [Abstract][Full Text] [Related]
32. Targeted therapies for hepatocellular carcinoma.
Skelton MR; O'Neil B
Clin Adv Hematol Oncol; 2008 Mar; 6(3):209-18. PubMed ID: 18391920
[TBL] [Abstract][Full Text] [Related]
33. Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
Itokawa N; Atsukawa M; Tsubota A; Okubo T; Arai T; Nakagawa A; Kondo C; Iwakiri K
Int J Clin Oncol; 2016 Aug; 21(4):676-683. PubMed ID: 26701173
[TBL] [Abstract][Full Text] [Related]
34. The advanced development of molecular targeted therapy for hepatocellular carcinoma.
Yan T; Yu L; Zhang N; Peng C; Su G; Jing Y; Zhang L; Wu T; Cheng J; Guo Q; Shi X; Lu Y
Cancer Biol Med; 2022 Jun; 19(6):802-17. PubMed ID: 35699406
[TBL] [Abstract][Full Text] [Related]
35. Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review.
Tang H; Cao Y; Jian Y; Li X; Li J; Zhang W; Wan T; Liu Z; Tang W; Lu S
Biosci Trends; 2022 May; 16(2):130-141. PubMed ID: 35431288
[TBL] [Abstract][Full Text] [Related]
36. Advanced hepatocellular carcinoma. Review of targeted molecular drugs.
Alves RC; Alves D; Guz B; Matos C; Viana M; Harriz M; Terrabuio D; Kondo M; Gampel O; Polletti P
Ann Hepatol; 2011; 10(1):21-7. PubMed ID: 21301005
[TBL] [Abstract][Full Text] [Related]
37. Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies.
Gnoni A; Licchetta A; Memeo R; Argentiero A; Solimando AG; Longo V; Delcuratolo S; Brunetti O
Medicina (Kaunas); 2019 Nov; 55(12):. PubMed ID: 31766556
[TBL] [Abstract][Full Text] [Related]
38. Targeted Therapy for Hepatocellular Carcinoma.
Ohri N; Kaubisch A; Garg M; Guha C
Semin Radiat Oncol; 2016 Oct; 26(4):338-43. PubMed ID: 27619254
[TBL] [Abstract][Full Text] [Related]
39. Oral chemotherapy for the treatment of hepatocellular carcinoma.
Yamamoto S; Kondo S
Expert Opin Pharmacother; 2018 Jun; 19(9):993-1001. PubMed ID: 29913090
[TBL] [Abstract][Full Text] [Related]
40. Evolution of Systemic Therapy for Hepatocellular Carcinoma.
Finn RS; Zhu AX
Hepatology; 2021 Jan; 73 Suppl 1():150-157. PubMed ID: 32380571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
